Betamethasone Phonophoresis For Vitiligo
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 40 years old?
Source: NCT07267273, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cairo University
- Trial code
- NCT07267273
- Record updated
- 5 December 2025
- Original description
Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin.Read full original descriptionShow less
Effect of Betamethasone Phonophoresis in Treatment of Vitiligo
Vitiligo is a skin disorder that results in the formation of depigmented patches or hypopigmented macules due to selective destruction or reduction of melanocytes the cells that produce pigment in our skin.
Vitiligo affects 0.1-2% of the World's population. People of all skin types and all ages can be affecte. In most of the cases, white patches develop or expand slowly overtime, and in some cases it never progress and remains stable . Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as stable or unstable based on the activity of disease.
Steroids act as anti-inflammatory and immunosuppressant agents. Even if different classes of steroids are now available, the mid- potent ones (e.g. betamethasone dipropionate 0.05% cream, 0.05% clobetasol propionate ointment) are usually preferred for the treatment of young patients .
Now days, topical corticosteroids are the most commonly prescribed agents in treatment of dermatologic conditions .Almost all treatments of vitiligo have borrowed from therapies whose prime targets have been another disease.
Inclusion: Male and female patients diagnosed with vitiligo; Medically and psychologically stable patients; Good cognitive abilities to understand the requirements of the study; All patients enrolled to the study will have their informed consent; they had no contraindications to the use of therapeutic ultrasound.
Exclusion: History of spontaneous re-pigmentation of lesions; Active bacterial/viral infection; Pregnancy or lactation; Immunosuppression; Alcohol abuse; Presence of skin characteristics that may interfere with study assessment; Patients on other immune suppressants and phototherapy; Patients currently participating in any other clinical study; Uncooperative patients.